Indobest Health Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-01-2025
- Paid Up Capital ₹ 0.10 M
as on 01-01-2025
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 4.75%
(FY 2020)
- Profit 3.21%
(FY 2020)
- Ebitda 246.77%
(FY 2020)
- Net Worth 32.21%
(FY 2020)
- Total Assets 41.64%
(FY 2020)
About Indobest Health Science
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mukesh Pandey and Arjun Talukdar serve as directors at the Company.
- CIN/LLPIN
U85100MH2011PTC221434
- Company No.
221434
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Aug 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Sangli, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Indobest Health Science Private Limited offer?
Indobest Health Science Private Limited offers a wide range of products and services, including Salon, Spa Kits & Equipments, Beauty Salon Furniture, Exercise & Fitness Equipment, Tourmaline Heating Mat, Exercise Bikes & Fitness Equipments, Slimming Machines, Massage Equipments & Spa Devices, Massage Chair, Massage Bed, Massage Equipment.
Who are the key members and board of directors at Indobest Health Science?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Pandey  | Director | 17-Oct-2020 | Current |
| Arjun Talukdar | Director | 08-Apr-2021 | Current |
Financial Performance of Indobest Health Science.
Indobest Health Science Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.75% increase. The company also saw a slight improvement in profitability, with a 3.21% increase in profit. The company's net worth Soared by an impressive increase of 32.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indobest Health Science?
In 2019, Indobest Health Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Indobest Health Science?
Unlock and access historical data on people associated with Indobest Health Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indobest Health Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indobest Health Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
